Results 221 to 230 of about 21,694,813 (356)

DEVICE DEVELOPMENT FOR LONG-TERM SYSTEMIC ORAL BIOLOGIC DRUG DELIVERY

, 2021
Benjamin P. Wankum
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Navigating Drug-Drug Interactions in Clinical Drug Development: A Tutorial. [PDF]

Clin Transl Sci
Lohy Das J, Ajavon-Hartmann AT, Schmith VGD.   +2 more
europepmc   +1 more source

Development of polycomplex carriers based on hydroxypropyl cellulose and Carbopol® for gastroretentive drug delivery

U. N. Zabolotnaya, Venera R. Timergalieva, Shamil F. Nasibullin, Rouslan I. Moustafine   +3 more
openalex   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Add-on combination therapy with monoclonal antibodies: Implications for drug development. [PDF]

J Prev Alzheimers Dis
Cummings J, Burstein AH, Fillit H.
europepmc   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Scoping review of the role of pharmacometrics in model-informed drug development. [PDF]

J Pharmacokinet Pharmacodyn
Bhat AG, Shin E, Roy A, Ramanathan M.
europepmc   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development. [PDF]

Drug Dev Res
Bobolea SȘ, Hinoveanu MI, Dimitriu A, Brașoveanu MA, Iliescu CN, Dinu-Pîrvu CE, Ghica MV, Anuța V, Popa L, Prisada RM.   +9 more
europepmc   +1 more source